Abstract:Thyroid gland has a key role in maintaining the body homeostasis. Thyroxine is the main hormone secreted from the thyroid gland, its effect being predominantly achieved after the intracellular conversion of thyroxine to triiodothyronine, which exhibits a higher affinity for the receptor complex, thus modifying gene expression of the target cells. Amiodarone is one of the most commonly used antiarrhythmics in the treatment of a broad spectrum of arrhythmias, usually tachyarrhythmias. Amiodarone contains a large proportion of iodine, which is, in addition to the intrinsic effect of the medication, the basis of the impact on thyroid function. It is believed that 15%-20% of patients treated with amiodarone develop some form of thyroid dysfunction. Amiodarone may cause amiodarone-induced hypothyroidism (AIH) or amiodarone-induced thyrotoxicosis (AIT). AIT is usually developed in the areas with too low uptake of iodine, while AIH is developed in the areas where there is a sufficient iodine uptake. Type 1 AIT is more common among patients with an underlying thyroid pathology, such as nodular goiter or Graves' (Basedow's) disease, while type 2 mostly develops in a previously healthy thyroid. AIH is more common in patients with previously diagnosed Hashimoto's thyroiditis. Combined types of the diseases have also been described. Patients treated with amiodarone should be monitored regularly, including laboratory testing and clinical examinations, to early detect any deviations in the functioning of the thyroid gland. Supplementary levothyroxine therapy is the basis of AIH treatment. In such cases, amiodarone therapy quite often need not be discontinued. Type 1 AIT is treated with thyrostatic agents, like any other type of thyrotoxicosis. If possible, the underlying amiodarone therapy should be discontinued. In contrast to type 1 AIT, the basic pathophysiological substrate of which is the increased synthesis and release of thyroid hormones, the basis of type 2 AIT is destructive thyroiditis caused by amiodarone, desethylamiodarone as its main metabolite, and an increased iodine uptake. Glucocorticoid therapy is the basis of treatment for this type of disease.

Effects of amiodarone therapy on thyroid function

The effects of amiodarone on QT dispersion in patients with atrial fibrillation

Amiodarone-Induced Thyroid Dysfunction: A Clinical Update

AMIODARONE AND THYROID DYSFUNCTION

Adverse effects of amiodarone therapy in adults with congenital heart disease

A Refractory Case of Amiodarone Thyrotoxicosis

The effect of amiodarone on heart rate variability in patients with idiopathic dilated cardiomyopathy

Cardiac evaluation in amiodarone-induced thyroid dysfunction with suspected cardiac ischemia?: a case report and review of the literature

Amiodarone: A Comprehensive Guide for Clinicians

Thyroid Dysfunction in Advanced Heart Failure Patients and Its Correlation with Amiodarone Therapy: A Two-Year Study

2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction

The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review

Case Report: Amiodarone-induced multi-organ toxicity

Amiodarone-induced Thyroid Dysfunction in Taiwan: a Retrospective Cohort Study

Amiodarone - a 'broad spectrum' antiarrhythmic drug

The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches

When amiodarone-induced thyroiditis meets cardiomyopathy with excessive trabeculation: a case report

The roles of thyroidectomy in patients with amiodarone-induced thyrotoxicosis: A systematic review

Amiodarone-induced thyrotoxicosis: should surgery be considered?

A Case of Amiodarone-Induced Thyrotoxicosis Presenting With Methimazole-Induced Agranulocytosis

Refractory amiodarone-induced thyrotoxicosis requiring adjunctive cholestyramine treatment